Loading...
•
Mar 31, 2024
Acumen Q1 2024 Earnings Report
Acumen Pharmaceuticals reported financial results for the first quarter of 2024 and provided a business update.
Key Takeaways
Acumen Pharmaceuticals reported a net loss of $14.9 million for the first quarter of 2024. As of March 31, 2024, cash, cash equivalents and marketable securities totaled $296.6 million, which is expected to support current clinical and operational activities into the first half of 2027.
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024.
Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024.
Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027.
The first patient was dosed in ALTITUDE-AD, a Phase 2 study investigating the efficacy and safety of sabirnetug for the treatment of early AD.
Forward Guidance
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...